Sorana Segal-Maurer, MD

Sorana Segal-Maurer, MD, offers clinical insights on treating patients with HIV who have viral mutations, including M184V, highlighting guideline recommendations.

HIV: Treating Patients with Viral Mutations

Video content above is prompted by the following questions:

Patients with viral mutations, including 

, require a different and more tailored therapeutic approach to manage their disease.

Can you share your treatment approach for a patient with a viral mutation, such as 

What are the current treatment guideline recommendation on this?

Videos

An expert on HIV discusses recent real-world studies and research on patient-reported outcomes, detailing treatment algorithms under investigation and their reported tolerability.

Recent Studies on HIV Treatments and Patient-Reported Outcomes

Recent real-world studies and studies on patient-reported outcomes have reported on the overall impact of their therapeutic regimen for HIV. Can you share some more about the results seen in these studies?

Sorana Segal-Maurer, MD, reviews research evaluating the efficacy of B/F/TAF compared with other HIV treatment regimens, including dolutegravir plus tenofovir/FTC.

Head-to-Head Comparisons on B/F/TAF Compared With Other HIV Regimens

Video content above is prompted by the following question(s):

Studies have run head-to-head comparisons on the efficacy of B/F/TAF compared to other regimens, like dolutegravir + tenofovir/FTC, stressing patient adherence and the outcomes associated.

What are the notable differences in efficacy were seen in these studies?


An infectious disease specialist discusses the differences in binding affinity between dolutegravir and bictegravir and how it informs treatment selection.

Differences in Binding Affinity Between Integrase Inhibitors in HIV

Integrase inhibitors like dolutegravir and bictegravir bind to the active site of the integrase and as such suppress the HIV virus; they are integral to modern therapeutic algorithms.

Can you explain the differences in binding affinity between dolutegravir and bictegravir and does this impact your treatment selection?


Sorana Segal-Maurer, MD

Articles